Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.